Dec 30, 2019
NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...
524
Dec 28, 2019
2020 SOHO Annual meeting : Eighth annual meeting of the Society of Hematologic Oncology
The eighth annual meeting of the Society of Hematologic Oncology (SOHO 2020) is scheduled for September 9–12, 2020. Organized by its...
249
Dec 28, 2019
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
CARTITUDE-4 Ciltacabtagene Autoleucel A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA),...
1,424
Dec 27, 2019
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)
KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...
570
Dec 25, 2019
FDA Approved NDMM Transplant Eligible: Daratumumab + Bortezomib, Thalidomide and Dexamethasone
On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma...
169
Dec 25, 2019
FDA Approved for NDMM Transp. Ineligible: Daratumumab + Lenalidomide & Dexamethasone
On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with...
66
Dec 21, 2019
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed...
82
Dec 21, 2019
American Cancer Society - What is Multiple Myeloma?
American Cancer Society - What is Multiple Myeloma? What is Multiple Myeloma? If you have multiple myeloma or are close to someone who...
428
Dec 20, 2019
The MAMMOTH study: Monoclonal Antibodies in Multiple Myeloma: Outcomes after Therapy Failure
MAMMOTH study Multicenter, retrospective study to investigate the natural history and outcomes of patients with MM refractory to CD38...
107
Dec 20, 2019
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors A Phase...
106
Dec 19, 2019
NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis...
32
Dec 19, 2019
NCT04036461: Phase 1 - A Study of CC-99712, a BCMA Antibody-Drug Conjugate in relapsed MM
Study CC-99712-MM-001 This is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical...
555
Dec 19, 2019
NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04045795:...
79
Dec 19, 2019
NCT04096066: Phase 3: EMN 20 - A Trial That Compare Two Treatments TIE - NDMM - KRd Vs Rd
NCT04096066: Phase 3: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRd vs Rd)...
84
Dec 19, 2019
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
776
Dec 18, 2019
FDA Approved for RRMM: Xpovio (selinexor) tablets + Dexamethasone
On July 3, 2019, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) in...
57
Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
1,082
Dec 14, 2019
Showering While You Have a Central Venous Catheter | Memorial Sloan Kettering
Showering While You Have a Central Venous Catheter | Memorial Sloan Kettering
142
Dec 14, 2019
NCT04144387: IFM2017 Evaluation of the Impact of the Update SMM Criteria on the Natural History SMM
IFM 2017-04 - CARRISMM NCT04144387: Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New...
94